The company manufactures and supplies a variety of crop protection products including insecticides, herbicides, and fungicides for both domestic and international agricultural markets. It generates revenue through direct sales of its own branded formulations and by providing contract manufacturing services for other agrochemical firms.
The company lacks a durable moat as evidenced by extremely thin net margins (averaging 1.1%) and a business model heavily reliant on generic formulations and job work. While they hold 257 product registrations, the lack of proprietary molecules or significant brand power results in low pricing power and returns that barely exceed the cost of capital.
Management reinvests primarily in expanding manufacturing capacity and working capital to support volume growth, but the incremental returns are modest. The introduction of a small dividend suggests a shift toward shareholder returns, though the high debt-to-equity ratio for a low-margin business indicates aggressive financial leverage.
The company's razor-thin net margins of 1.1% left no room for error when input costs spiked and generic competition intensified. Over-leveraged with a 0.78 debt-to-equity ratio, the business was crushed by interest payments as working capital became trapped in bloated inventory and aging receivables. The lack of proprietary products meant they were price-takers in a commodity race to the bottom, while governance lapses and related-party transactions eventually eroded investor trust, leading to a permanent impairment of capital as the business failed to earn its cost of capital.
RichFakir rates Aristo Bio-Tech & Lifescience Ltd's business quality as mediocre — 48/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Aristo Bio-Tech & Lifescience Ltd is trading about 39% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Aristo Bio-Tech & Lifescience Ltd is: Not rated. A mediocre business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Aristo Bio-Tech & Lifescience Ltd's fair value is about ₹63 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →